National Organization for Rare Disorders, Inc.

The National Organization for Rare Disorders (NORD®) is a leading patient advocacy organization dedicated to improving the health and well-being of individuals affected by rare diseases. Established in 1983, NORD's core mission is to drive advances in care, research, and policy for the rare disease community. The organization is headquartered in Danbury, Connecticut, with additional offices in Quincy, Massachusetts, and Washington, D.C.

NORD provides a comprehensive suite of services, including advocacy, research support, educational initiatives, and patient assistance programs. Key offerings include the IAMRARE® program, which facilitates natural history studies and patient registries, and seed grants for academic research into rare diseases. NORD also maintains a Rare Disease Database, offering information on over 1,200 rare conditions, and administers patient assistance programs that help with co-pays, medication, and access to specialized medical care. The organization's Rare Action Network® mobilizes grassroots advocacy, and its NORD Rare Disease Centers of Excellence network connects medical centers to foster expertise and collaborative research.

Pamela K. Gavin was appointed Chief Executive Officer of NORD in May 2024. In recent activities, NORD announced its 2025 Industry Innovation and Rare Impact Award Honorees in July 2025 and allocated $245,000 in seed grant funding for rare disease research in August 2025. The organization also released its 2025 State Report Card in February 2026, evaluating rare disease policies across all 50 states, and hosted its 2025 NORD Breakthrough Summit in October 2025. NORD continues to serve as a central hub for the rare disease community, representing over 340 patient advocacy organizations and more than 40 Rare Disease Centers of Excellence.

Latest updates

NORD Bolsters Policy Muscle with Veteran Appointments

Event summary

  • NORD appointed Michael J. Beard as Vice President of Federal and Global Public Policy and Cara Tenenbaum, JD, MBA, as Director of Regulatory Affairs.
  • Michael Beard brings over 20 years of experience from Congress, HHS, and the United Nations Foundation.
  • Cara Tenenbaum has nearly two decades of experience at the intersection of policy, regulation, and patient advocacy, including a prior role at the FDA.
  • These appointments are framed as strengthening NORD’s ability to support its member organizations and advance patient-centered policy.
  • NORD represents over 30 million Americans with rare diseases and hundreds of patient advocacy organizations.

The big picture

NORD’s strategic investments in policy leadership reflect the growing recognition of the need for coordinated advocacy in the rare disease space. With over 30 million Americans affected, the organization's influence extends beyond direct patient care to shaping regulatory frameworks and influencing legislative priorities. The appointments signal a proactive approach to navigating an increasingly complex policy landscape where rare disease advocacy often faces resource constraints and competing interests.

What we're watching

Policy Impact
The effectiveness of Beard’s global policy strategy will hinge on NORD’s ability to navigate increasingly complex international healthcare regulations and competing national interests.
Regulatory Alignment
Tenenbaum’s success will depend on her ability to influence FDA processes and expedite treatment approvals while maintaining safety standards, a delicate balance given current political pressures.
Advocacy Coordination
The degree to which NORD can maintain its position as a trusted policy partner to hundreds of patient advocacy organizations will determine its overall influence and impact on rare disease policy.

NORD Partners with OpenEvidence to Leverage AI in Rare Disease Resource Development

Event summary

  • NORD and OpenEvidence have partnered to create AI-powered rare disease resources for clinicians and patients.
  • The collaboration will build a library of over 3,000 rare disease summaries, updated monthly.
  • OpenEvidence is a medical AI platform used by hundreds of thousands of U.S. physicians.
  • NORD operates with a network of over 350 disease-specific patient organizations and 46 Rare Disease Centers of Excellence.

The big picture

The partnership reflects a growing trend of leveraging AI to address information gaps in specialized medical fields, particularly those with fragmented knowledge bases like rare diseases. This collaboration positions both NORD and OpenEvidence to capitalize on the increasing demand for accessible and up-to-date medical information, potentially impacting patient outcomes and clinical workflows. The move also highlights the increasing importance of AI in democratizing access to medical expertise, especially for underserved patient populations.

What we're watching

Adoption Rate
The success of this partnership hinges on the adoption rate of the AI-powered resources by clinicians and patients; slow uptake could limit the impact and ROI for both organizations.
Data Accuracy
Maintaining the accuracy and reliability of the AI-generated content, even with expert review, will be critical to establishing trust and avoiding potential liability.
Competitive Landscape
Other medical information providers may respond to this initiative, potentially intensifying competition and requiring NORD and OpenEvidence to continually innovate to maintain their advantage.

Rare Disease Awareness Run Highlights $400B Unmet Medical Need

Event summary

  • Over 100 Southern Californians participated in a Rare Disease Day 5K run/walk on February 28, 2026, benefiting the National Organization for Rare Disorders (NORD®).
  • The event highlighted the challenges faced by over 4 million Californians and 30+ million Americans living with rare diseases.
  • Maddox Briney, a 9-year-old with KIF1A Associated Neurological Disorder (KAND), participated to raise awareness of his condition, one of approximately 600 worldwide.
  • Rare diseases collectively impact 1 in 10 Americans, with more than half being children, and fewer than 5% have approved treatments.

The big picture

The Rare Disease Day run underscores the significant, yet often overlooked, public health challenge posed by rare diseases. With a collective impact rivaling major illnesses like cancer and Alzheimer's, the $400 billion in medical costs associated with these conditions represents a substantial unmet need and a potential area for innovation and investment. The involvement of A Snail's Pace demonstrates a growing trend of businesses aligning with social causes and offering specialized solutions to underserved patient populations.

What we're watching

Funding Landscape
Increased awareness events like this may spur greater investment in rare disease research and therapeutic development, but the fragmented nature of the field presents challenges for ROI.
Diagnostic Advances
The story of Chandler Peppers highlights the need for improved diagnostic tools and physician education; progress in these areas will be crucial to reducing the average five-year diagnostic delay.
Patient Access
The high medical costs associated with rare diseases will continue to pressure payers and policymakers to find sustainable solutions for patient access and affordability.

Rare Disease Treatment Gap Fuels $400 Billion Burden, Spurs Advocacy Push

Event summary

  • Over 30 million Americans are estimated to be living with rare diseases, a significant and often overlooked public health challenge.
  • Less than 5% of the more than 10,000 known rare diseases have approved treatments, highlighting a critical gap in therapeutic development.
  • Families often face a 5-7 year diagnostic odyssey, incurring substantial medical costs estimated at $400 billion annually.
  • NORD is mobilizing communities nationwide on February 28 for “Show Your Stripes” to raise awareness and advocate for research and policy changes.

The big picture

The rare disease landscape represents a substantial unmet medical need and a significant economic burden, exceeding $400 billion annually. NORD's advocacy efforts, coupled with the involvement of major pharmaceutical players, signal a growing focus on this underserved patient population, but the low treatment approval rate underscores the challenges ahead. The 'Show Your Stripes' campaign and related initiatives are likely to intensify scrutiny of regulatory pathways and incentivize innovation in rare disease therapeutics.

What we're watching

Policy Response
The effectiveness of NORD's lobbying efforts and the resulting policy changes will be crucial in accelerating rare disease research and treatment access, particularly given the substantial economic burden.
Innovation Pipeline
The low treatment approval rate suggests a significant innovation gap; tracking the pipeline of therapies in development and the success rate of clinical trials will be essential.
Diagnostic Advances
The lengthy diagnostic delays highlight a need for improved diagnostic tools and techniques; the adoption rate of new technologies and their impact on time-to-diagnosis will be a key indicator.

NORD Launches CME Challenge to Address Rare Disease Diagnostic Delays

Event summary

  • NORD launched the 'Earn Your Stripes: Rare Disease CME Challenge' on February 23, 2026, running through March 31.
  • The initiative aims to improve early diagnosis and management of rare diseases among healthcare professionals.
  • Over 30 million Americans live with a rare disease, often facing years-long diagnostic delays.
  • Medlive has partnered with NORD for six years, delivering education to over 76,000 clinicians, patients, and caregivers.
  • 93% of participating clinicians reported positive changes to their practice after previous Medlive/NORD programming.

The big picture

The initiative highlights a systemic problem: a significant gap in rare disease education for clinicians, contributing to delayed diagnoses and poorer patient outcomes. This challenge represents a targeted effort to address this gap, leveraging a proven partnership between NORD and Medlive. The program's reliance on video-based learning suggests a broader trend towards digital continuing education in the healthcare sector.

What we're watching

Adoption Rate
The challenge's success hinges on broad adoption by primary care physicians and pediatricians, which will determine the impact on diagnostic timelines and patient outcomes.
Content Efficacy
The effectiveness of the video-first CME content will be crucial; Medlive's past success rate (93% positive change) sets a high bar for demonstrable impact.
Scalability
NORD's ability to expand the program beyond the initial challenge period and integrate it into ongoing clinician training will be key to long-term impact on rare disease awareness.

Rare Disease Policy Disparities Persist Despite Incremental State Progress

Event summary

  • NORD’s 2025 State Report Card graded states on rare disease policies, assigning a national average grade of “B”.
  • Four states (Colorado, Delaware, Maine, and New Jersey) received the highest grade of “A”.
  • Thirteen states received failing grades for medical nutrition coverage, a key area of concern.
  • Federal agencies’ reduced enforcement of short-term insurance plans has shifted patient protection responsibility to state laws.
  • Nineteen states currently lack Rare Disease Advisory Councils (RDACs), limiting patient input on policy.

The big picture

NORD's report highlights the ongoing challenge of equitable healthcare access in the US, particularly for individuals with rare diseases. The decentralization of healthcare policy, driven by federal regulatory shifts, places increased pressure on states to fill the void and protect vulnerable populations. The lack of uniform standards creates a patchwork system where access to care is heavily dependent on geographic location.

What we're watching

Policy Shifts
The continued reliance on state-level regulation for short-term insurance plans will likely lead to increased lobbying efforts and policy divergence across states, creating complexity for patients and providers.
RDAC Expansion
The pace at which remaining states establish RDACs will be a key indicator of patient advocacy effectiveness and the willingness of policymakers to incorporate patient perspectives into healthcare decisions.
Nutrition Coverage
How states address the widespread lack of medical nutrition coverage will reveal the political will to support vulnerable patients and potentially influence reimbursement models for specialized therapies.

NIH Director to Spotlight Innovation at NORD Rare Disease Symposium

Event summary

  • The second annual NORD Rare Disease Scientific Symposium will be held April 14–15, 2026, in Arlington, VA.
  • NIH Director Dr. Jay Bhattacharya will headline the event, emphasizing the need for accelerated research and therapeutic development.
  • The symposium anticipates over 600 attendees, building on the 600+ who attended the inaugural event.
  • The agenda includes sessions on innovative clinical trial designs, drug repurposing, and regulatory pathways, including the FDA’s plausible mechanism pathway.

The big picture

The NORD symposium highlights the increasing focus on rare disease therapeutics, a market segment attracting significant investment due to unmet medical needs and potential for orphan drug exclusivity. The emphasis on innovative clinical trial designs and regulatory pathways reflects the challenges of developing treatments for small patient populations and the need for adaptive approaches. The involvement of the NIH Director underscores the government’s commitment to accelerating progress in this area.

What we're watching

Regulatory Shifts
The FDA’s embrace of plausible mechanism pathways could significantly alter the development timeline for rare disease therapies, potentially incentivizing investment in novel approaches but also introducing new evidentiary hurdles.
Data Integration
The symposium's focus on registries, real-world data, and patient-generated data suggests a growing recognition of their importance; the ability to effectively integrate these data sources will be critical for demonstrating therapeutic value and securing coverage.
Funding Models
With diverse funding models being examined, the sustainability of rare disease research will depend on the ability of advocacy groups, academia, and industry to forge collaborative and financially viable partnerships.
CID: 700